Teva hits major biosimilar milestones with FDA nod and regulatory filings
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Over the past few months, Apollo Hospitals has entered into MoUs with multiple national and international air ambulance service providers
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The presentations underscore the company’s deep expertise in dermatology and immunology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Subscribe To Our Newsletter & Stay Updated